2026-08-28
On 15 May 2026 the revised Implementation Regulations of the Drug Administration Law took effect, with Article 32 expressly allowing segmented (split-site) production of qualifying innovative drugs under a...
2026-08-28
The "Pilot Work Plan for Expanding Opening in the Wholly Foreign-Owned Hospital Sector" (NHC, MOFCOM et al., Guowei Yizhengfa No. 36) permits wholly foreign-owned hospitals in nine provincial...
2026-08-28
Wholly-foreign-owned hospitals are piloted in nine regions — Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island — under the Nov-2024 pilot plan; outside those areas foreign-invested...
2026-08-28
Imported medical devices still require NMPA registration by risk class (I/II/III), and Class II/III overseas manufacturers must register their production sites with the NMPA before any China market entry....
2026-08-28
China's innovative-drug market is projected to exceed ¥1.3 trillion in 2026, with 2025 out-licensing deals reaching roughly US$135 billion and the first quarter of 2026 alone surpassing US$60 billion....
2026-08-28
In 2026 the national foreign investment negative list stays at 29 items, but regulators have committed to "timely reduction", with services as the priority and telecom, internet, education, culture...
2026-08-28
The State Council's National Health 15th Five-Year Plan (Guo Fa No. 23) explicitly calls for expanding the wholly foreign-owned hospital pilot and steadily advancing international medical services pilots....